KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $409000.0.

  • Adaptive Biotechnologies' Capital Expenditures rose 1889.53% to $409000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 5077.84%. This contributed to the annual value of $3.7 million for FY2024, which is 6574.74% down from last year.
  • Adaptive Biotechnologies' Capital Expenditures amounted to $409000.0 in Q3 2025, which was up 1889.53% from $655000.0 recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Capital Expenditures peaked at $22.0 million during Q2 2021, and registered a low of $80000.0 during Q4 2024.
  • Its 5-year average for Capital Expenditures is $5.0 million, with a median of $2.8 million in 2023.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Capital Expenditures skyrocketed by 87397.26% in 2021, and later crashed by 9383.67% in 2024.
  • Over the past 5 years, Adaptive Biotechnologies' Capital Expenditures (Quarter) stood at $9.2 million in 2021, then crashed by 72.5% to $2.5 million in 2022, then tumbled by 48.94% to $1.3 million in 2023, then tumbled by 93.84% to $80000.0 in 2024, then surged by 411.25% to $409000.0 in 2025.
  • Its Capital Expenditures stands at $409000.0 for Q3 2025, versus $655000.0 for Q2 2025 and $1.3 million for Q1 2025.